

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2019

<https://marketpublishers.com/r/S9E8EAD523DEN.html>

Date: November 2019

Pages: 58

Price: US\$ 2,000.00 (Single User License)

ID: S9E8EAD523DEN

Abstracts

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2019, provides an overview of the Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline landscape.

Systemic onset juvenile idiopathic arthritis (also known as Systemic juvenile idiopathic arthritis (sJIA)) is a disorder featuring inflammation, characterized by high spiking fevers, salmon-colored rash that comes and goes, and arthritis. Symptoms are extreme fatigue accompanied by high fevers that rise daily to 102 F (39 C) or even higher and rapidly return to normal levels or below. Fever spikes often occur at approximately the same time every day. A faint salmon colored skin rash characteristically comes and goes and does not itch. Poor appetite, nausea, and weight loss are common. There is also commonly swelling of the lymph glands, enlargement of the spleen and liver, and sore throat. Some patients develop inflammation around the heart (pericarditis) and lungs (pleuritis), with occasional fluid accumulation around heart (pericardial effusion) and lungs (pleural effusion).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile

Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 2 and 2 respectively.

Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Systemic Idiopathic Juvenile Arthritis - Overview
Systemic Idiopathic Juvenile Arthritis - Therapeutics Development Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Systemic Idiopathic Juvenile Arthritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Systemic Idiopathic Juvenile Arthritis - Companies Involved in Therapeutics Development
BioXpress Therapeutics SA
Eli Lilly and Co
Jinyu Bio-technology Co Ltd
Johnson & Johnson
Mycenax Biotech Inc
Regeneron Pharmaceuticals Inc
Systemic Idiopathic Juvenile Arthritis - Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMAB-806 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sarilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Simponi Aria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Systemic Idiopathic Juvenile Arthritis - Dormant Projects

Systemic Idiopathic Juvenile Arthritis - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Systemic Idiopathic Juvenile Arthritis - Pipeline by BioXpress Therapeutics SA, H2 2019

Systemic Idiopathic Juvenile Arthritis - Pipeline by Eli Lilly and Co, H2 2019

Systemic Idiopathic Juvenile Arthritis - Pipeline by Jinyu Bio-technology Co Ltd, H2 2019

Systemic Idiopathic Juvenile Arthritis - Pipeline by Johnson & Johnson, H2 2019

Systemic Idiopathic Juvenile Arthritis - Pipeline by Mycenax Biotech Inc, H2 2019

Systemic Idiopathic Juvenile Arthritis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Systemic Idiopathic Juvenile Arthritis - Dormant Projects, H2 2019

Systemic Idiopathic Juvenile Arthritis - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

BioXpress Therapeutics SA

Eli Lilly and Co

Jinyu Bio-technology Co Ltd

Johnson & Johnson

Mycenax Biotech Inc

Regeneron Pharmaceuticals Inc

I would like to order

Product name: Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/S9E8EAD523DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S9E8EAD523DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970